HarrisonSA, RolphT, KnottM, et al.FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. J Hepatol, 2024; 81(3):562–576; doi: 10.1016/j.jhep.2024.04.034
2.
TackeF, HornP, WongVWS, et al.EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol, 2024; 81(3):492–542; doi: 10.1016/j.jhep.2024.04.031
YounossiZM, GolabiP, PaikJM, et al.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology, 2023; 77(4):1335–1347; doi: 10.1097/HEP.0000000000000004
5.
FalamarziK, MalekpourM, TaftiMF, et al.The role of FGF21 and its analogs on liver associated diseases. Front Med (Lausanne), 2022; 9:967375; doi: 10.3389/fmed.2022.967375
6.
PostA, DamWA, SokootiS, et al.Circulating FGF21 concentration, fasting plasma glucose, and the risk of type 2 diabetes: Results from the PREVEND study. J Clin Endocrinol Metab, 2023; 108(6):1387–1393; doi: 10.1210/clinem/dgac729
7.
MarkanKR. Defining “FGF21 Resistance” during obesity: Controversy, criteria and unresolved questions. F1000Res, 2018; 7:289; doi: 10.12688/f1000research.14117.1
8.
DiercksGF, JanssenWM, van BovenAJ, et al.Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol, 2000; 86(6):635–638; doi: 10.1016/s0002-9149(00)01042-0
9.
SuzukiM, UeharaY, Motomura-MatsuzakaK, et al.βKlotho is required for Fibroblast Growth Factor (FGF) 21 signaling through FGF Receptor (FGFR) 1c and FGFR3c. Mol Endocrinol, 2008; 22(4):1006–1014; doi: 10.1210/me.2007-0313
10.
BadmanMK, PissiosP, KennedyAR, et al.Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab, 2007; 5(6):426–437; doi: 10.1016/j.cmet.2007.05.002
11.
DunsheeDR, BainbridgeTW, KljavinNM, et al.Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J Biol Chem, 2016; 291(11):5986–5996; doi: 10.1074/jbc.M115.710582
12.
RichterMM, ThomsenMN, SkytteMJ, et al.Effect of a 6-week carbohydrate-reduced high-protein diet on levels of FGF21 and GDF15 in people with type 2 diabetes. J Endocr Soc, 2024; 8(4):bvae008; doi: 10.1210/jendso/bvae008
13.
FiorenzaM, ChecaA, SandsdalRM, et al.Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids. Cell Rep Med, 2024; 5(7):101629; doi: 10.1016/j.xcrm.2024.101629
14.
PattM, KarkossaI, KriegL, et al.FGF21 and its underlying adipose tissue-liver axis inform cardiometabolic burden and improvement in obesity after metabolic surgery. EBioMedicine, 2024; 110:105458; doi: 10.1016/j.ebiom.2024.105458
15.
PostA, DamWA, GroothofD, et al.Higher circulating FGF21, lower protein intake, and lower muscle mass: Associations with a higher risk of mortality. J Intern Med, 2025; 298(1):2–15; doi: 10.1111/joim.20099
16.
Díaz-DelfínJ, HondaresE, IglesiasR, et al.TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: Involvement of JNK1 in the FGF21 pathway. Endocrinology, 2012; 153(9):4238–4245; doi: 10.1210/en.2012-1193
17.
TuckerWJ, TuckerB, JanuszewskiAS, et al.Association of circulating fibroblast growth factor 21 levels with all-cause and cardiovascular mortality: The multi-ethnic study of atherosclerosis. Clin Chim Acta, 2024; 555:117799; doi: 10.1016/j.cca.2024.117799
18.
LaegerT, HenaganTM, AlbaradoDC, et al.FGF21 is an endocrine signal of protein restriction. J Clin Invest, 2014; 124(9):3913–3922; doi: 10.1172/JCI74915
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
